A case series of five hypertensive type 2 diabetes patients showing reduction in blood pressure and mean arterial pressure reduction in ambulatory blood pressure monitoring with remogliflozin etabonate 200 mg coprescribed with recent onset anti-hypertensive drugs
Abstract
Introduction. Hypertension is commonly occurring in type 2 diabetes and metabolic syndrome and inflammation are a well-known part of this disease entity. The data of using remogliflozin in Indian patient is not known as this is a very recently approved molecule for the treatment of type 2 diabetes. Here we look into a case series of five patients who had their ambulatory blood pressure monitoring (ABPM) done at baseline and again after 14 days of therapy of adding remogliflozin etabonate to recent onset antihypertensive druges.
Methods. We analysed the ABPM results of five patients after taking their informed consent at baseline and two weeks post-treatment initiation with remogliflozin alongside with recent onset antihypertensive drugs. We used paired t test for statistical analysis of the two readings of each patient to come to a conclusion.
Results. We found a statistically significant decrease in mean arterial pressure (MAP) reflected by a p value of 0.0277 and the reduction in mean awake time systolic blood pressure (SBP) was also very close to statistical significance as seen by the p value of 0.0541.
Conclusions. Remogliflozin etabonate when co-prescribed with antihypertensive drugs shows a significant reduction in MAP as well as reduction in SBP although most of the contribution seems to be coming from the antihypertensive molecule itself.
Keywords: type 2 diabetesremogliflozin etabonatemean arterial pressuresystolic blood pressureambulatory blood pressure monitoring
References
- de Ferranti SD, de Boer IH, Fonseca V, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Circulation. 2014; 130(13): 1110–1130.
- de Ferranti SD, de Boer IH, Fonseca V, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Circulation. 2014; 130(13): 1110–1130.
- Weber MA, Bakris GL, Jamerson K, et al. ACCOMPLISH Investigators. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol. 2010; 56(1): 77–85.
- Bakris G, Briasoulis A, Dahlof B, et al. ACCOMPLISH Investigators, ACCOMPLISH Trial investigators, ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008; 359(23): 2417–2428.
- Semlitsch T, Jeitler K, Berghold A, et al. Long-term effects of weight-reducing diets in people with hypertension. Cochrane Database Syst Rev. 2016; 3: CD008274.
- Dobbins RL, O'Connor-Semmes R, Kapur A, et al. Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients. Diabetes Obes Metab. 2012; 14(1): 15–22.
- Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. Can J Cardiol. 2018; 34(5): 575–584.
- Kario K, Okada K, Kato M, et al. Twenty-Four-Hour Blood Pressure–Lowering Effect of a Sodium-Glucose Cotransporter 2 Inhibitor in Patients With Diabetes and Uncontrolled Nocturnal Hypertension. Circulation. 2019; 139(18): 2089–2097.
- Nakano S, Katsuno K, Isaji M, et al. Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice. J Clin Exp Hepatol. 2015; 5(3): 190–198.
- Baker WL, Smyth LR, Riche DM, et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014; 8(4): 262–75.e9.